September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
A 6-Week Ocular Pharmacokinetic Study of ENV905 (difluprednate) Intracameral Implant or Durezol in the Albino Rabbit
Author Affiliations & Notes
  • Rozemarijn S Verhoeven
    Envisia Therapeutics, Morrisville, North Carolina, United States
  • RiLee Robeson
    Envisia Therapeutics, Morrisville, North Carolina, United States
  • Andres Garcia
    Envisia Therapeutics, Morrisville, North Carolina, United States
  • Brian C Gilger
    NCSU, Raleigh, North Carolina, United States
  • David Culp
    Powered Research, Morrisville, North Carolina, United States
  • Craig B Struble
    Covance, Madison, Wisconsin, United States
  • Lee Hamm
    Intertek, El Dorado Hills, California, United States
  • Thomas Grizzle
    Toxicology Services, Chapel Hill, North Carolina, United States
  • Tomas Navratil
    Envisia Therapeutics, Morrisville, North Carolina, United States
  • Rhett M Schiffman
    Envisia Therapeutics, Morrisville, North Carolina, United States
  • Footnotes
    Commercial Relationships   Rozemarijn Verhoeven, Envisia Therapeutics (E), Envisia Therapeutics (P); RiLee Robeson, Envisia Therapeutics (E); Andres Garcia, Envisia Therapeutics (E), Envisia Therapeutics (P); Brian Gilger, Envisia Therapeutics (C); David Culp, None; Craig Struble, None; Lee Hamm, None; Thomas Grizzle, Envisia Therapeutics (C); Tomas Navratil, Envisia Therapeutics (E); Rhett Schiffman, Envisia Therapeutics (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5711. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Rozemarijn S Verhoeven, RiLee Robeson, Andres Garcia, Brian C Gilger, David Culp, Craig B Struble, Lee Hamm, Thomas Grizzle, Tomas Navratil, Rhett M Schiffman; A 6-Week Ocular Pharmacokinetic Study of ENV905 (difluprednate) Intracameral Implant or Durezol in the Albino Rabbit. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5711.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the ocular and systemic pharmacokinetics (PK) of intracameral ENV905 compared with topical Durezol in the albino rabbit. ENV905 is being developed as a treatment for inflammation and pain associated with ocular surgery.

Methods : Male NZW rabbits (2/group/terminal time point) were administered a single bilateral intracameral administration of ENV905 (40ug/eye), or Durezol administered according to the clinical standard of care (Days 1-14 QID, Days 15-21 BID, Days 22-28 QD, 1925ug/eye), and were followed for up to 42 days. Durezol samples were obtained 30 minutes post-dose. Ocular matrixes were analyzed using LC-MS/MS for difluprednate (DFBA, parent) and desacetyl difluprednate (DFB, metabolite) and plasma was analyzed for DFB only. Data was assessed for non-compartmental PK parameters using WinNonlin.

Results : Exposure to DFB was generally consistent in each matrix over the 28-day Durezol dosing period at 30 minutes post-dose (AUC = cornea>trabecular meshwork (TM)>conjunctiva>iris/ciliary body (ICB)> aqueous humor (AH)>retina>plasma) and samples were mostly BLQ by Day 42. For ENV905, DFB peaked on Day 1 (AUC = ICB>cornea>TM>AH>conjunctiva> retina>plasma), had markedly decreased in concentration in all matrixes by Day 7, and was BLQ in all samples by Day 21. When ENV905 and Durezol were compared, DFB Cmax was increased for ENV905; AUC was considerably higher for Durezol in cornea and TM, and was higher in the other matrixes with the exception of ICB which was higher for ENV905.

Conclusions : Durezol administration resulted in consistent exposure to DFB in plasma and ocular samples over 28 days, with the greatest exposure over time in cornea and TM. DFB concentrations for ENV905 peaked on Day 1 at higher concentrations than Durezol, but dissipated in a tapering manner over 14 days, with the greatest exposure over time in the ICB. There was no detectable exposure to the TM after day 14 which may reduce the incidence of steroid responsive IOP spikes following cataract surgery. Administration of ENV905 at the site of inflammation following cataract surgery allows for significant dose sparing, targeted distribution to the tissues of interest, and decreased cumulative exposure to the corticosteroid.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×